Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan-Yan Yu

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|August 18, 2004
Promoting hepatic growth factor in the treatment of heavy type hepatitis and severe chronic hepatitis: a multicenter clinical studyJing-Hang Xu, Yan-Yan Yu, Chong-Wen Si, et al.
Acta Pharmacologica Sinica|July 24, 2020
Sarsasapogenin improves adipose tissue inflammation and ameliorates insulin resistance in high-fat diet-fed C57BL/6J miceYan-Yan Yu, Shi-Chao Cui, Tian-Nan Zheng, et al.
Acta Pharmacologica Sinica|May 26, 2018
Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob/ob miceMei Zhang, Zhi-Fu Xie, Run-Tao Zhang, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|December 21, 2010
[Comparison of lamivudine or interferon monotherapy and sequential therapy in chronic hepatitis B: a random controlled trial]Jing-hang Xu, Yan-yan Yu, Chong-wen Si, et al.
Acta Pharmacologica Sinica|July 30, 2020
AMPK activator C24 inhibits hepatic lipogenesis and ameliorates dyslipidemia in HFHC diet-induced animal modelsShui-Mei Sun, Zhi-Fu Xie, Yang-Ming Zhang, et al.
World Journal of Clinical Cases|October 17, 2022
One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or CJing-Hang Xu, Sa Wang, Da-Zhi Zhang, et al.
Journal of Viral Hepatitis|June 23, 2022
240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or CJing-Hang Xu, Ya-Nan Fan, Yan-Yan Yu, et al.
World Journal of Clinical Cases|July 5, 2021
Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeksXiao-Fan Chen, Ya-Nan Fan, Chong-Wen Si, et al.
Medicine|August 16, 2019
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48Rong-Yue Liang, Jing-Hang Xu, Chong-Wen Si, et al.
Hepatology International|April 14, 2017
CSH guidelines for the diagnosis and treatment of drug-induced liver injuryYue-Cheng Yu, Yi-Min Mao, Cheng-Wei Chen, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|August 18, 2004
Promoting hepatic growth factor in the treatment of heavy type hepatitis and severe chronic hepatitis: a multicenter clinical studyJing-Hang Xu, Yan-Yan Yu, Chong-Wen Si, et al.
Acta Pharmacologica Sinica|July 24, 2020
Sarsasapogenin improves adipose tissue inflammation and ameliorates insulin resistance in high-fat diet-fed C57BL/6J miceYan-Yan Yu, Shi-Chao Cui, Tian-Nan Zheng, et al.
Acta Pharmacologica Sinica|May 26, 2018
Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob/ob miceMei Zhang, Zhi-Fu Xie, Run-Tao Zhang, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|December 21, 2010
[Comparison of lamivudine or interferon monotherapy and sequential therapy in chronic hepatitis B: a random controlled trial]Jing-hang Xu, Yan-yan Yu, Chong-wen Si, et al.
Acta Pharmacologica Sinica|July 30, 2020
AMPK activator C24 inhibits hepatic lipogenesis and ameliorates dyslipidemia in HFHC diet-induced animal modelsShui-Mei Sun, Zhi-Fu Xie, Yang-Ming Zhang, et al.
World Journal of Clinical Cases|October 17, 2022
One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or CJing-Hang Xu, Sa Wang, Da-Zhi Zhang, et al.
Journal of Viral Hepatitis|June 23, 2022
240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or CJing-Hang Xu, Ya-Nan Fan, Yan-Yan Yu, et al.
World Journal of Clinical Cases|July 5, 2021
Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeksXiao-Fan Chen, Ya-Nan Fan, Chong-Wen Si, et al.
Medicine|August 16, 2019
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48Rong-Yue Liang, Jing-Hang Xu, Chong-Wen Si, et al.
Hepatology International|April 14, 2017
CSH guidelines for the diagnosis and treatment of drug-induced liver injuryYue-Cheng Yu, Yi-Min Mao, Cheng-Wei Chen, et al.
Pageof 8